$NNUP: Building a Platform in Specialty Materials. Initiating Coverage of @NNUP_IR with a Valuation Target of $2.50. buff.ly/b20U3aE
$ICU: We forecast @SeaStarMedical revenue growing from about $2M in 2026 to $16M in 2028. The catalysts behind that path: buff.ly/KRAlpD3
#MedTech #SmallCaps
Read the full analysis: buff.ly/HfgzeyS
$ICU @SeaStarMedical QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients buff.ly/HfgzeyS by @DavidBautz
$SNES @SenesTech Positive Takeaways of Virtual Meeting & of Longtime Institutional Shareholder Increased Stake buff.ly/V7hJsAR
$TRX $TRX.TO: @TRXGoldCorp Record Q4 Caps Fiscal 2026 at Top of Guidance; Drilling Ramp-Up Sets Stage for Expansion buff.ly/XXvHqHn
Investors are not Giving $COSM Credit for Growth #GlobalHealthcare #GlobalHealthcare #DigitalHealth buff.ly/SiKb9Kn
$YOUL: First-half revenue topped RMB1.9B, up 100%+ YoY, per the company. Youlife Group CSO Stanley Yang breaks down what drove it and the organic growth outlook from here: buff.ly/a2vfsnp
#ChinaStocks #SmallCaps #Staffing
Read the full transcript: buff.ly/UP1CDNw
Zacks SCR retweeted
No Botox biosimilar has been approved since Botox launched in 1989. $AEON is developing ABP-450 to change that, with FDA studies expected in 2027. Our take in 60 seconds: buff.ly/qqOtKt5
#biotech #smallcapstocks #biosimilars
Investors are not Giving $COSM Credit for Growth #GlobalHealthcare #GlobalHealthcare #DigitalHealth buff.ly/SiKb9Kn
$AEON: The Botox Files - A Biosimilar in the Making #DrugDevelopment #BiotechInnovation #TherapeuticNeurotoxins buff.ly/u6JDUgM
Get updates on small caps like $POET, $HOVR, and $GRRR directly to your inbox. Subscribe to Zacks SCR’s complimentary daily, weekly, or new coverage alerts: buff.ly/HOqY3DL
#SmallCaps #MicroCaps #EquityResearch #Investing
$MRDN Growth examples include recent acquisition of Fairbet in Malta & sponsorship and also Expanse Studios’ strategic distribution agreement in Serbia #AI #igaming #softwaresolutions #technology buff.ly/wUk4bjd
$ARWR: @ArrowheadPharma Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases buff.ly/BUqS7mb by @DavidBautz
$IMNN: Patient Testimonial Highlights Potential for Ovarian Cancer Treatment #biopharma #immunotherapy #vaccines #DNA buff.ly/QXD0FoX
$GMEX: 87% of hotels reported staffing shortages in 2025, per the AHLA. @GMEXRobotics is building AI robots aimed at that gap, starting in commercial kitchens: buff.ly/uMoaA0d
#Robotics #PhysicalAI #SmallCaps
